Home
/
Inhibitor Therapeutics, Inc.
/
Financials
/
Quarterly
Inhibitor Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Inhibitor Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$0
Nov 14, 2022
Q2
2022
Jun 30, 2022
$0
Aug 12, 2022
Q1
2022
Mar 31, 2022
$0
May 13, 2022
Q3
2022
Sep 30, 2021
$0
Nov 14, 2022
Q2
2022
Jun 30, 2021
$0
Aug 12, 2022
Q1
2022
Mar 31, 2021
$0
May 13, 2022
Q3
2021
Sep 30, 2020
$0
Nov 12, 2021
Q2
2021
Jun 30, 2020
$0
Aug 13, 2021
Q1
2021
Mar 31, 2020
$0
May 14, 2021
Q3
2020
Sep 30, 2019
$0
Nov 16, 2020
Q2
2020
Jun 30, 2019
$0
Aug 12, 2020
Q1
2020
Mar 31, 2019
$0
May 1, 2020
Q3
2017
Sep 30, 2017
$0
Oct 31, 2017
Q2
2017
Jun 30, 2017
$0
Jul 31, 2017
Q1
2016
Mar 31, 2017
$0
May 8, 2017
Q3
2016
Sep 30, 2016
$0
Oct 31, 2016
Q2
2017
Jun 30, 2016
$0
Jul 31, 2017
Q1
2016
Mar 31, 2016
$0
May 8, 2017
Q3
2015
Sep 30, 2015
$0
Nov 4, 2015
Q2
2016
Jun 30, 2015
$0
Aug 12, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($712.2K)
Nov 13, 2025
Q3
2025
Jun 30, 2025
($659.9K)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($659.9K)
Aug 13, 2025
Q2
2025
Mar 31, 2025
($632.8K)
Aug 13, 2025
Q3
2025
Mar 31, 2025
($632.8K)
Nov 13, 2025
Q1
2025
Mar 31, 2025
($632.8K)
May 14, 2025
Q3
2025
Sep 30, 2024
($731.0K)
Nov 13, 2025
Q3
2025
Jun 30, 2024
($501.7K)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($501.7K)
Aug 13, 2025
Q2
2025
Mar 31, 2024
($684.7K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($684.7K)
May 14, 2025
Q3
2025
Mar 31, 2024
($684.7K)
Nov 13, 2025
Q3
2024
Sep 30, 2023
($664.8K)
Nov 12, 2024
Q3
2024
Jun 30, 2023
($654.5K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($654.5K)
Aug 6, 2024
Q3
2024
Mar 31, 2023
($539.6K)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($539.6K)
May 13, 2024
Q2
2024
Mar 31, 2023
($539.6K)
Aug 6, 2024
Q3
2023
Sep 30, 2022
($77.7K)
Nov 13, 2023
Q3
2023
Jun 30, 2022
($77.6K)
Nov 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($741.2K)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($695.8K)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($674.6K)
May 14, 2025
Q3
2025
Sep 30, 2024
($813.2K)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($585.1K)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($774.8K)
May 14, 2025
Q3
2024
Sep 30, 2023
($759.5K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($742.5K)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($629.7K)
May 13, 2024
Q3
2023
Sep 30, 2022
($70.0K)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($70.8K)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($93.5K)
May 15, 2023
Q3
2022
Sep 30, 2021
($66.2K)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($62.6K)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($167.8K)
May 13, 2022
Q3
2021
Sep 30, 2020
($302.8K)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($315.0K)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($385.4K)
May 14, 2021
Q3
2020
Sep 30, 2019
($682.9K)
Nov 16, 2020
Q2
2020
Jun 30, 2019
($635.5K)
Aug 12, 2020